| Literature DB >> 32049002 |
Yoshiaki Tanaka1, Bilal Cakir1, Yangfei Xiang1, Gareth J Sullivan2, In-Hyun Park3.
Abstract
Human brain organoid systems offer unprecedented opportunities to investigate both neurodevelopmental and neurological disease. Single-cell-based transcriptomics or epigenomics have dissected the cellular and molecular heterogeneity in the brain organoids, revealing a complex organization. Similar but distinct protocols from different labs have been applied to generate brain organoids, providing a large resource to perform a comparative analysis of brain developmental processes. Here, we take a systematic approach to compare the single-cell transcriptomes of various human cortical brain organoids together with fetal brain to define the identity of specific cell types and differentiation routes in each method. Importantly, we identify unique developmental programs in each protocol compared to fetal brain, which will be a critical benchmark for the utility of human brain organoids in the future.Entities:
Keywords: brain development; brain organoid; cortical spheroids; developmental trajectory; hCOs; hESC; protocol comparison; scRNA-seq; stem cells
Mesh:
Year: 2020 PMID: 32049002 PMCID: PMC7043376 DOI: 10.1016/j.celrep.2020.01.038
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1.Schematic View of the Culture System Generating hCOs
Guided protocols are originated from Eiraku et al., 2008, while non-guided protocols are from Lancaster et al., 2013. Timeline of neural induction, differentiation, and maturation step is shown across protocols.
Comparison of Medium Compositions and Single-Cell Transcriptome Libraries across Different Protocols
| Components | ||||||||
|---|---|---|---|---|---|---|---|---|
| Induction | ||||||||
| Basal medium | DMEM-F12 | Glasgow-MEM | DMEM-F12 | DMEM-F12 | Neurobasal | DMEM-F12 | DMEM-F12 | DMEM-F12 |
| Supplement | KSR | KSR | KSR | KSR | Gem21 NeuroPlex | KSR | KSR + N2 | KSR + N2 |
| β-Me | O | O | O | O | O | |||
| TGFβ inh. | O | O | O | O | O | O | ||
| BMP inh. | O | O | O | O | O | |||
| WNT inh. | O | O | O | |||||
| SHH inhi. | O | |||||||
| Differentiation | ||||||||
| Basal medium | Neurobasal | DMEM-F12 | Neurobasal | Neurobasal | Neurobasal | DMEM-F12 + Neurobasal (1:1) | DMEM-F12 + Neurobasal (1:1) | DMEM-F12 + Neurobasal (1:1) |
| Supplement | N2 | N2 + LC | B27 (−A) | B27 (−A) | Gem21 NeuroPlex + NEAA | N2 + B27 (−A) + NEAA | N2 + B27 (−A) + NEAA | N2 + B27 (−A) + NEAA |
| β-Me | O | O | O | |||||
| Insulin | O | O | O | |||||
| SHH inh. | O | |||||||
| Growth factor | FGF2/EGF | FGF2/EGF | FGF2 | |||||
| Matrigel | Yes | Yes | ||||||
| Maturation | ||||||||
| Basal medium | Neurobasal | DMEM-F12 | Neurobasal | Neurobasal | Neurobasal | DMEM-F12 + Neurobasal (1:1) | DMEM-F12 + Neurobasal (1:1) | DMEM-F12 + Neurobasal (1:1) |
| Supplement | N2 | N2 + FBS+ LC+ B27 (+A) | B27 (+A) | B27 (+A) | Gem21 NeuroPlex + NEAA | N2 + B27 (+A) + NEAA | N2 + B27 (+A) + NEAA | N2 + B27 (+A) + NEAA |
| β-Me | O | O | O | |||||
| Insulin | O | O | O | |||||
| Growth factor | BDNF, NT-3 | BDNF, NT-3 | BDNF. GDNF. NT-3 | BDNF | BDNF | |||
| Matrigel | Yes | Yes | Yes | |||||
| Others | PDGF-AA, IGF-1, T3, Ketoconazole, Clemastine, GSK2656157 | cAMP + Ascorbic acid | cAMP + Ascorbic acid | Ascorbic acid + HEPES + Sodium bicarbonate, air-liquid interface | ||||
| Single-cell RNA sequencing | ||||||||
| SRA ID | SRA: SRP121791 | SRA: SRP191528 | SRA: SRP096997 | SRA: SRP131980 | SRA: SRP139859 | SRA: SRP105219 | SRA: SRP083140 | SRA: SRP174405 |
| Age | ~5 weeks | ~6 months | 105 days | 10 weeks | 6 months | ~79 days | ~6 months | 75 days |
| Cell count | 13,747 | 81,524 | 4,953 | 3,743 | 3,295 | 23,707 | 43,706 | 13,009 |
PDGF, platelet-derived growth factor; KSR, KnockOut™ Serum Replacement; β-Me, β-mercaptoethanol; Inh., inhibitor; SRA ID, short read archive ID; N2, N-2 Supplement; LC, liquid concentrate; B27, B-27™ supplement; NT-3, neurotrophin-3; PDGF-AA, platelet-derived growth factor-AA; T3, triiodothyronine; NEAA, non-essential amino acid; BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; +A, with vitamine A; −A, without vitamine A.
Figure 2.Comparative Analyses of Cell Compositions among Different hCO Protocols
(A and B) UMAP plot of 190,022 single cells distinguished by cell types (A) and protocols (B). AS, astrocyte; BRC, BMP-related cell; CBC, ciliabearing cell; CN, cortical excitatory neuron; GPC, glia progenitor cell; IN, interneuron; ME, mesodermal cell; NEC, neuroepithelial cell; OL, oligodendrocyte; PGC, proteoglycan-expressing cell; RGC, radial glia cell; UPRC, unfolded-protein-response-related cell.
(C) The presence of cell types in each organoid protocol and human fetal brain. Cell types with >0.25% of cells are denoted with a plus sign F, Fiddes et al. (2018); V, Velasco et al. (2019); B, Birey et al. (2017); M, Madhavan et al. (2018); T, Trujillo et al. (2019); X, Xiang et al., (2017); Q, Quadrato et al. (2017); G, Giandomenico et al. (2019).
(D) UMAP-based heatmap showing representative genes of cilium, BMP signal, and proteoglycan.
(E) Gene set enrichment analysis (GSEA) of gene signatures for neuron, replicating NPC, astrocyte, oligodendrocyte, endothelial cell, and microglia. The enrichment and depletion (−log10(FDR)) are scaled with red and blue color, respectively.
(F) Comparison of organoid ages and brain developing stage. Dots represent scRNA-seq datasets. Color scheme for protocols corresponds to Figure 2B. Pearson correlation coefficient and its statistical significance are also shown.
See also Figure S1.
Figure 3.Comparative Analyses of Developmental Paths and Transcriptional Biases among Different Protocols
(A–C) SNN graph visualization for differentiation trajectory.
(A) Color scheme for cell types corresponds to that in Figure 2A. Differentiation directions (arrows) were determined by pseudotime in Figure S2A.
(B) Estimated trajectory backbone from the SNN graph.
(C) Comparison of differentiation trajectory among different protocols.
(D) SNN-graph-based heatmap showing the expression of representative genes in each bypass.
(E) The number and characteristics of differentially expressed genes in each organoid protocol. The analysis was performed with the oldest organoid in each protocol.
(F) GSEA of Gene Ontology (GO) terms between in vivo fetal brain and in vitro organoid.
(G) Enrichment of disease-related genes in each organoid.
(H) The ratio of excitatory and inhibitory neurons among different protocols.
(I) Comparison of regional identify with NKX2–1 expression among the dorsal and ventral brain organoid. scRNA-seq datasets for the ventral organoid were obtained from Birey et al. (2017) and Xiang et al. (2017).
See also Figure S2.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Deposited Data | ||
| scRNA-seq for hCOs | SRA: SRP121791 | |
| scRNA-seq for hCOs | SRA: SRP180337 | |
| scRNA-seq for hCOs | SRA: SRP191528 | |
| scRNA-seq for hCOs | SRA: SRP096997 | |
| scRNA-seq for hCOs | SRA: SRP131980 | |
| scRNA-seq for hCOs | SRA: SRP139859 | |
| scRNA-seq for hCOs | SRA: SRP105219 | |
| scRNA-seq for hCOs | SRA: SRP083140 | |
| scRNA-seq for hCOs | SRA: SRP174405 | |
| scRNA-seq for human fetal brains | GSE: GSE104276 | |
| scRNA-seq for human fetal and adult brains | SRA: SRP057196 | |
| RNA-seq for | BrainSpan | |
| Time-course bulk RNA-seq for hCOs by | GSE: GSE120700 | |
| Software and Algorithms | ||
| Bamtofastq (v1.1.2) | 10x Genomics | |
| fastq-dump (v2.9.4) | NCBI | |
| CellRanger (v2.1.0) | 10x Genomics | |
| R (v3.5.0) | N/A | |
| Seurat (v3.0) | ||
| Monocle (v2.99.3) | ||
| Scran (v1.10.2) | ||
| DICER | ||
| GOstats (v2.24.0) | ||
| GSEAPY (v0.9.3) | N/A | |
| Bioconductor (v3.8) | N/A | |
| GSEA (v2.2.2) | ||